Global Personalized Cell Therapeutic Market Growth 2025-2031
The global Personalized Cell Therapeutic market size is predicted to grow from US$ 16490 million in 2025 to US$ 31530 million in 2031; it is expected to grow at a CAGR of 11.4% from 2025 to 2031.
Personalized cells are undifferentiated stem cells that can be divided to generate offspring cells designated as specialized or personalized stem cells. Specialized treatment of numerous chronic diseases such as autoimmune and cancer through vaccinating living cells into the body of patients to boost the personalized cell therapy market. As there are multiple types of living cells such as immature and mature living cell, blood and bone marrow cell and embryonic stem cells that are mainly utilized in personalized cell therapy.
Several manufacturers are conducting numerous clinical trials to develop new personalized cell therapies for chronic diseases such as cancer, diabetes and other autoimmune diseases. For example, in April 2019, Orgenesis Inc. received approval from the Institutional Review Board (IRB) to collect liver biopsy samples from patients at the Rambam Medical Center in Israel. Samples were collected to confirm the safety and efficacy of hepatocytes for individualized cell replacement therapy in patients with insulin-dependent diabetes mellitus following total or partial pancreatectomy. Hence, increasing number of studies is expected to boost the growth of the global personalized cell therapy market.
LP Information, Inc. (LPI) ' newest research report, the ?Personalized Cell Therapeutic Industry Forecast? looks at past sales and reviews total world Personalized Cell Therapeutic sales in 2024, providing a comprehensive analysis by region and market sector of projected Personalized Cell Therapeutic sales for 2025 through 2031. With Personalized Cell Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Personalized Cell Therapeutic industry.
This Insight Report provides a comprehensive analysis of the global Personalized Cell Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Personalized Cell Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Personalized Cell Therapeutic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Personalized Cell Therapeutic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Personalized Cell Therapeutic.
This report presents a comprehensive overview, market shares, and growth opportunities of Personalized Cell Therapeutic market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Embryonic Stem Cells
Adult Stem Cell
Induced Pluripotent Cells
Other
Segmentation by Application:
Cardiovascular Diseases
Neurological Disorders
Diabetes
Oncology
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
AbbVie Inc
Bausch Health Companies Inc
Teva Pharmaceutical Industries Ltd
Cipla
Lupin
Sun Pharmaceuticals Industries Ltd
Hikma Pharmaceuticals PLC
AstraZeneca
GSK Plc
Pfizer Inc
Amneal Pharmaceuticals LLC
Alvogen
F. Hoffmann-La Roche Ltd
Amgen Inc
Jazz Pharmaceuticals, Inc
Amicus Therapeutics, Inc
MeiraGTx Limited
Rocket Pharmaceuticals, Inc
Gilead Sciences, Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Personalized Cell Therapeutic market?
What factors are driving Personalized Cell Therapeutic market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Personalized Cell Therapeutic market opportunities vary by end market size?
How does Personalized Cell Therapeutic break out by Type, by Application?
Personalized cells are undifferentiated stem cells that can be divided to generate offspring cells designated as specialized or personalized stem cells. Specialized treatment of numerous chronic diseases such as autoimmune and cancer through vaccinating living cells into the body of patients to boost the personalized cell therapy market. As there are multiple types of living cells such as immature and mature living cell, blood and bone marrow cell and embryonic stem cells that are mainly utilized in personalized cell therapy.
Several manufacturers are conducting numerous clinical trials to develop new personalized cell therapies for chronic diseases such as cancer, diabetes and other autoimmune diseases. For example, in April 2019, Orgenesis Inc. received approval from the Institutional Review Board (IRB) to collect liver biopsy samples from patients at the Rambam Medical Center in Israel. Samples were collected to confirm the safety and efficacy of hepatocytes for individualized cell replacement therapy in patients with insulin-dependent diabetes mellitus following total or partial pancreatectomy. Hence, increasing number of studies is expected to boost the growth of the global personalized cell therapy market.
LP Information, Inc. (LPI) ' newest research report, the ?Personalized Cell Therapeutic Industry Forecast? looks at past sales and reviews total world Personalized Cell Therapeutic sales in 2024, providing a comprehensive analysis by region and market sector of projected Personalized Cell Therapeutic sales for 2025 through 2031. With Personalized Cell Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Personalized Cell Therapeutic industry.
This Insight Report provides a comprehensive analysis of the global Personalized Cell Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Personalized Cell Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Personalized Cell Therapeutic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Personalized Cell Therapeutic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Personalized Cell Therapeutic.
This report presents a comprehensive overview, market shares, and growth opportunities of Personalized Cell Therapeutic market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Embryonic Stem Cells
Adult Stem Cell
Induced Pluripotent Cells
Other
Segmentation by Application:
Cardiovascular Diseases
Neurological Disorders
Diabetes
Oncology
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
AbbVie Inc
Bausch Health Companies Inc
Teva Pharmaceutical Industries Ltd
Cipla
Lupin
Sun Pharmaceuticals Industries Ltd
Hikma Pharmaceuticals PLC
AstraZeneca
GSK Plc
Pfizer Inc
Amneal Pharmaceuticals LLC
Alvogen
F. Hoffmann-La Roche Ltd
Amgen Inc
Jazz Pharmaceuticals, Inc
Amicus Therapeutics, Inc
MeiraGTx Limited
Rocket Pharmaceuticals, Inc
Gilead Sciences, Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Personalized Cell Therapeutic market?
What factors are driving Personalized Cell Therapeutic market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Personalized Cell Therapeutic market opportunities vary by end market size?
How does Personalized Cell Therapeutic break out by Type, by Application?
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
